Axsome Therapeutics, Inc. (AXSM) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $184.37: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum.
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on CNS disorders, with three FDA-approved commercial products: AUVELITY (MDD), SUNOSI (EDS), and SYMBRAVO (migraine), generating $638.5M in 2025 revenues (66% annual growth). The pipeline is led by... Read more
Sell if holding. Engine safety override at $184.37: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: RSI 60 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductAUVELITY, SUNOSI, and SYMBRAVO10-K Item 1A: 'We are substantially dependent on the success of our products ... Apart from AUVELITY, SUNOSI, and SYMBRAVO, we have no other products which have received regulatory approval.'
- MEDIUMpipelineAXS-05 for AD agitation10-K Item 1A: 'Breakthrough Therapy designation by the FDA for AXS-05 for the treatment of AD agitation'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $184.37: Quality below floor (4.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Rich valuation; Negative price momentum. Chart setup: RSI 60 mid-range, Bollinger mid-band. Prior stop was $171.99. Score 5.2/10, moderate confidence.
Take-profit target: $201.51 (+9.3% upside). Prior stop was $171.99. Stop-loss: $171.99.
Concentration risk — Product: AUVELITY, SUNOSI, and SYMBRAVO; Quality below floor (4.0 < 4.0).
Axsome Therapeutics, Inc. trades at a P/E of N/A (forward 32.3). TrendMatrix value score: 3.9/10. Verdict: Sell.
26 analysts cover AXSM with a consensus score of 4.3/5. Average price target: $224.
What does Axsome Therapeutics, Inc. do?Axsome Therapeutics is a fully integrated biopharmaceutical company focused on CNS disorders, with three FDA-approved...
Axsome Therapeutics is a fully integrated biopharmaceutical company focused on CNS disorders, with three FDA-approved commercial products: AUVELITY (MDD), SUNOSI (EDS), and SYMBRAVO (migraine), generating $638.5M in 2025 revenues (66% annual growth). The pipeline is led by AXS-05 for Alzheimer's disease agitation, with FDA Priority Review and a PDUFA date of April 30, 2026.